biotechnologyWave Life Sciences Obesity Trial Shows Baseline BMI Gaps Skew Efficacy Data Across Global Drug RaceSalvado•Mar 28, 2026
Pharmaceutical RegulationFDA Moves to Ban Compounded GLP-1 Drugs, Ending $400-Per-Month Alternative to $1,300 Brand Weight-Loss MedicationsViaNews Editorial Team•Feb 21, 2026
Healthcare & PharmaceuticalsPfizer Joins the Global Obesity Race: GLP-1 Market Entry Planned by 2028 Following Metsera AcquisitionViaNews Editorial Team•Feb 18, 2026
